forms dimers and then undergoes further maturation in the trans Golgi apparatus and post-Golgi compartments where it is multimerized. 9 In endothelial cells, the ultimate storage form for VWF consists of mature Weibel-Palade bodies. It is then secreted into plasma, upon which multimer length is shortening during microcirculatory transit via proteolysis by ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin Type 1 motif, member 13). Ultimately, VWF contributes to platelet thrombus formation. 10 Congenital decrease or dysfunction of VWF is the most common inherited bleeding disorder in humans and is known as von Willebrand Disease (VWD). 7, 11 The prevalence of this condition is estimated to range from 1 in 100-1 in 10 000. 12 Due to high clinical variability with regard to bleeding and numerous individuals with asymptomatic disease, the incidence of VWD has been proven more difficult to quantify. 13 HMWM can also decrease in cardiac disease states like aortic stenosis, hypertrophic cardiomyopathy with obstruction, and patients with left ventricular assist devices (LVAD).
14,15
| ASSAYS USED TO ASSESS VWF ACTIVITY
High molecular weight multimers play an essential role in primary hemostasis. The 2A subtype of congenital VWD is associated with a decrease in HMWM. Acquired type 2A VWD is seen in cardiac disease states where the entire blood volume is subjected to shear stress.
Assays to assess for HMWM are available for clinical use. In this section we highlight the currently available assays, which are summarized in Table 1 .
| VWF MULTIMERS
The concentration of VWF multimers in blood samples can be obtained by various techniques. Most commonly, analysis can be performed using gel electrophoresis. This gives a series of bands which correlate to each multimer group based upon molecular weight. As can be inferred, this leads to qualitative assessment of multimers. For quantification of multimers, electrophoresis gels can be subjected to densitometric scanning, which gives a relative concentration of individual bands. The ratio of the highest multimers (usually >15 mers) is divided by bands 2-15 of the patient's sample, which can be compared to the ratio observed for normal pooled plasma. 16 This approach yields a value near 1.0 for normal plasma. 17 A limitation of multimer analysis is that it is labor intensive and requires a high degree of expertise. Consequently, significant variation in results can be observed between different clinical laboratories.
| PLATELET FUNCTION ANALYZER 100
The platelet function analyzer 100 (PFA 100, Siemens Healthcare Diagnostics) is an automated system that is used to detect platelet dysfunction. The analyzer uses test cartridges coated with collagen/ adenosine diphosphate as well as collagen/epinephrine to induce platelet aggregation when whole blood samples are passed through a microscopic aperture. The time required for the aperture to close is referred to as the closure time. Closure time when performed with collagen/adenine diphosphate and collagen/epinephrine cartridges in the PFA 100 analyzer are referred to as CT-CADP and CT-CEPI, respectively. Normal CT-CADP is 66-126 s while normal CT-CEPI is <180 s. 18 The analyzer (in particular, collagen/ADP cartridge) can detect acquired platelet dysfunction despite concurrent aspirin use, as the results are not affected by aspirin therapy. 19 Additionally, these assays can be used to assess for VWD as well as other congenital platelet abnormalities. 20 The reasoning for this is that platelet-mediated aggregation is highly dependent on subendothelial and plasma HMWMs of VWF. In the presence of an inherited or acquired loss of HMWMs, closure time will be prolonged. CT-CADP is more sensitive than CT-CEPI for this (due to results not being affected by aspirin); however, the results are also affected by conditions such as anemia and thrombocytopenia. The turnaround time for the assay is 5-8 min. Thus, the advantage of this assay is its potential to be used as a point of care monitor for changes in HMWMs of VWF. 
| ADDITIONAL TECHNIQUES

| PATHOPHYSIOLOGY OF ACQUIRED VWD IN AORTIC STENOSIS
The association between calcific aortic stenosis and gastrointestinal bleeding has been known since the astute observation of Edward Heyde in 1958. 22 There were several reports of resolution of bleeding after SAVR. 23 Autopsy in such patients showed gastrointestinal (GI)
angiodysplasia as the possible source of bleeding. 24 The pathology underlying the association of calcific aortic stenosis with GI bleeding remained elusive until the proposition by Warkentin et al that acquired VWD was responsible for the etiology for this association. In their initial report published as a letter to the editor, they described two patients with aortic stenosis and GI angiodysplasia. 25 The HMWM of VWF were reduced preoperatively and the levels normalized after aortic valve replacement. GI bleeding resolved with SAVR in both patients. However, the initial study showing loss of HMWM of VWF in cardiac diseases was in children with non-cyanotic congenital heart defects, predominantly ventricular septal defect (VSD), and aortic stenosis. 26 The acquired VWD resolved following correction of the underlying cardiac defect. Tsai et al reported the susceptibility of VWF multimers to undergo proteolysis in response to shear stress. 27 Vincentelli et al 28 collagen-binding activity and loss of large multimers was also noted in a significant number of patients with severe aortic stenosis. After undergoing SAVR, these hemostatic parameters resolved. There was a direct correlation between severity of aortic stenosis (mean gradient) and abnormalities in VWF. Some patients with resolution of VWF abnormalities post operatively had recurrence of decreased VWF activity at 6 month follow up. The recurrence of the abnormality in part was attributed to the presence of patient-prosthesis mismatch.
Von Willebrand factor changes in response to shear stress play a key role in the development of acquired VWD in native or prosthetic aortic valve disease states. Shear stress within the diseased valve causes unfolding and elongation of the VWF polymer and exposes the A2 domain, 29 which is cleaved by ADAMTS13 causing a decrease in HMWM levels. 30 The smaller multimers do not have as strong a hemostatic effect as HMWM, the loss of which predisposes patients to bleeding. 9 There is an ongoing controversy as to whether the VWF pathway is also the etiology behind angiodysplasia formation. Some have attributed angiodysplasia formation to vascular aging. However, there is evidence to suggest a role for VWF in maintaining vascular integrity in addition to its primary hemostatic effect. 31 Starke et al demonstrated that inhibition of VWF expression via short interfering RNA in endothelial cells caused increased angiogenesis, evidenced by increased in vitro angiogenesis, increased VEGF receptor-2-dependent endothelial cell proliferation and migration, a decrease in integrin αvβ3 levels, and increased angiopoietin (Ang)-2 release. 32 This was significant in that it suggested a new role of VWF at the level of cellular expression of angiogenic factors.
| UTILITY OF VWF ASSAYS IN AORTIC VALVE REPLACEMENT
Studies of VWF activity in patients undergoing SAVR noted a significant increase in HMWM levels at 24 h after surgery. 28 The changes in VWF and real time blood flow were described in both humans and animal model by Van Belle. 17 A rabbit model was used with a vascular clamp in the ascending aorta to simulate aortic stenosis and create a high shear stress state. The vascular clamp had an inflatable cuff to simulate stenosis and the cuff could be deflated to reverse stenosis. A significant decrease in HMWM was observed at 5 min and even more so at 30 min after simulated stenosis compared to baseline (0.76 ± 0.07; P < 0.01 and 0.74 ± 0.07; P < 0.01, respectively).
In addition, an increase with complete recovery in HMWM was noted 
| PVL ASSESSMENT AND PROGNOSIS AFTER TAVR
The Achilles heel of the TAVR procedure is paravalvular regurgitation.
In the PARTNER and PARTNER 2 trials, in which Sapien valves (Edwards Lifesciences) were used, there was an increased mortality in patients with more than mild PVL resulting in aortic regurgitation. 34 This degree of PVL was not seen with the SAVR arm. It should also be noted that moderate or severe PVL noted post implant did not affect survival in studies using the self-expanding Core valve. 35 In assessment of PVL, a comprehensive evaluation of the degree of PVL is done using hemodynamic data, TEE, and aortic root angiography.
Van Belle et al 16 had high sensitivity, specificity, and negative predictive value for the presence of PVL. 16 HMWM ratio of less than 0.8 was also found to correlate with the presence of PVL. The study demonstrated that HMWM assessment and CT-CADP could be used both for intraoperative and follow-up assessment of the degree of PVL. 16 In fact, compared to TEE, CT-CADP, and HMWM ratio were better able to predict mortality at 1 year post-op.
Heart teams in many centers have begun to use the third generation Sapien S3 valve, which is associated with less PVL. 36 The 
| TRANSCATHETER AORTIC VALVE REPLACEMENT: ANOTHER CURE FOR HEYDE' S SYNDROME
Numerous case reports and studies have supported the finding that SAVR resolves GI bleeding in patients with severe aortic stenosis. [39] [40] [41] In particular, Warkentin et al displayed greater than 10 years correction of clinical and biological hemostatic abnormalities in two patients that underwent SAVR. 25 Godino et al evaluated the effect of TAVR on resolution of GI bleeding in patients with severe aortic stenosis. 42 Four hundred patients who underwent TAVR were evaluated retrospectively and six patients were found to have coexisting angiodysplastic lesions and aortic valve stenosis. At a mean follow up interval of 22 ± 15 months, 86% of patients had no recurrence of gastrointestinal bleeding.
One of the major limitations of the study was the retrospective nature and lack of laboratory evaluation of VWF multimers or platelet functional analysis. It can be hypothesized that the resolution of the acquired VWD restored normal hemostasis.
| VWF AND OTHER VALVULAR HEART DISEASES
Defects of HMWM of VWF are also seen in patients with aortic regurgitation, mitral insufficiency, and most patients with hypertrophic cardiomyopathy with resting obstruction. 28, 38, 43, 44 There is a probable association between VWF and left atrial appendage thrombus formation in patients with mitral valve stenosis. 45 
| VWF AND LVAD
In addition to native and prosthetic valve disease, high shear stress is also encountered with LVADs. There have been numerous studies to suggest that VWF is a player in the established association between LVAD and bleeding. 15, 48, 49 Van Belle et al performed VWF analysis in patients with the HeartMate-II LVAD (Thoratec Corporation). 17 The study found a significant reduction in HMWM as well as VWF:CB/ VWF:Ag ratio shortly after initiating the pump. The changes in HMWM were noted in both in vivo and in vitro models.
Acquired VWD confers additional risk of bleeding in patients with
LVADs, as they also routinely receive therapeutic anticoagulation.
Resolution of the loss of HMWM has been described after explantation of LVAD. Davis et al 50 14 | CONCLUSION A summary of the major referenced studies throughout this review has been included in Table 2 | 365 PVL, prosthetic valve dysfunction, hypertrophic cardiomyopathy with obstruction, and congenital heart defects. Ability to assess VWF multimers indirectly at the point of care with CT-CADP assay has significant clinical implications and is practice-changing in the field of TAVR, particularly for the detection of PVL.
